A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Conditions

• Marburg Virus Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - 50 Years

Healthy Volunteers

Accepted

Interventions

• rVSV∆G-MARV-GP — BIOLOGICAL
  rVSV∆G-MARV-GP
• Placebo — OTHER
  Placebo

Study Details

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Key Dates

Start date

Mar 27, 2026

Status verified

Apr 2026

Primary completion

Nov 30, 2027

Completion

Jul 31, 2028

Study Design

Enrollment

112 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Arms

• Experimental: rVSV∆G-MARV-GP
• Placebo Comparator: Placebo/Diluent

Primary Outcome Measure

Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity [ Time Frame: 14 Days ]

Central Contacts

• Johannes Beeslaar, MD
  212-328-7459
  [email protected]

Locations (2)

Find similar trials in Washington D.C., DC